FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361761038> ?p ?o ?g. }

• W4361761038 endingPage "365" @default.
• W4361761038 startingPage "365" @default.
• W4361761038 abstract "Background: Sodium-Glucose CoTransporter-2 [SGLT2] inhibitors, the -flozin group of drugs, which block glucose reuptake in the renal proximal tubule, are being increasingly used off-label to treat horses with refractory hyperinsulinemia. After two years of use by animals in our group, a horse on canagliflozin was incidentally noted to be hyperlipemic. Case Description: We have been following a cohort of equines (n=20) treated with SGLT2 inhibitors due to refractory hyperinsulinemia. The animals are owned by members of the Equine Cushing’s and Insulin Resistance Group (ECIR) and treated by their attending veterinarians. The index case was a 23 year old gelding with a 2 year history of recurring laminitis that began canagliflozin therapy to control hyperinsulinemia which was no longer responsive to metformin. Between 6-10 weeks post therapy, significant weight loss was noticed. Two days later he was hospitalized with colic symptoms and hyperlipemia but was bright, alert and eating well throughout. Canagliflozin was discontinued and triglycerides returned to normal reference values within 10 days. Subsequent study of 19 other horses on SGLT2 inhibitors revealed varying degrees of hypertriglyceridemia, all asymptomatic. Conclusion: While this class of drugs holds great promise for cases of refractory hyperinsulinemia and laminitis that do not respond to diet or metformin therapy, hypertriglyceridemia is a potential side effect. In our experience, animals remained asymptomatic and eating well. Further study of hypertriglyceridemia in horses on SGLT2 inhibitors and the possible mitigating effect of diet is indicated. To our knowledge, this is the first published report of hypertriglyceridemia with SGLT2 inhibitor treatment in equines." @default.
• W4361761038 created "2023-04-04" @default.
• W4361761038 creator A5006246332 @default.
• W4361761038 creator A5084050969 @default.
• W4361761038 date "2023-01-01" @default.
• W4361761038 modified "2023-09-30" @default.
• W4361761038 title "Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors" @default.
• W4361761038 cites W1493169197 @default.
• W4361761038 cites W1893550040 @default.
• W4361761038 cites W1968297309 @default.
• W4361761038 cites W1976098918 @default.
• W4361761038 cites W2009410609 @default.
• W4361761038 cites W2093724180 @default.
• W4361761038 cites W2105102980 @default.
• W4361761038 cites W2124551016 @default.
• W4361761038 cites W2153213785 @default.
• W4361761038 cites W2188994168 @default.
• W4361761038 cites W2301709502 @default.
• W4361761038 cites W2331147272 @default.
• W4361761038 cites W2734906620 @default.
• W4361761038 cites W2759467499 @default.
• W4361761038 cites W2889907695 @default.
• W4361761038 cites W2897214532 @default.
• W4361761038 cites W2902836599 @default.
• W4361761038 cites W2914703817 @default.
• W4361761038 cites W2917947380 @default.
• W4361761038 cites W2963230356 @default.
• W4361761038 cites W3121570312 @default.
• W4361761038 cites W3134853691 @default.
• W4361761038 cites W3160177741 @default.
• W4361761038 cites W3160641467 @default.
• W4361761038 cites W3166401170 @default.
• W4361761038 cites W3179657698 @default.
• W4361761038 cites W3185143147 @default.
• W4361761038 cites W3209635995 @default.
• W4361761038 cites W3211487790 @default.
• W4361761038 cites W3211684333 @default.
• W4361761038 cites W4200529355 @default.
• W4361761038 cites W4220698972 @default.
• W4361761038 cites W4226149301 @default.
• W4361761038 cites W4240693186 @default.
• W4361761038 cites W4280527826 @default.
• W4361761038 cites W4282966634 @default.
• W4361761038 cites W4293821063 @default.
• W4361761038 cites W4315567824 @default.
• W4361761038 doi "https://doi.org/10.5455/ovj.2023.v13.i3.14" @default.
• W4361761038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37026076" @default.
• W4361761038 hasPublicationYear "2023" @default.
• W4361761038 type Work @default.
• W4361761038 citedByCount "2" @default.
• W4361761038 countsByYear W43617610382023 @default.
• W4361761038 crossrefType "journal-article" @default.
• W4361761038 hasAuthorship W4361761038A5006246332 @default.
• W4361761038 hasAuthorship W4361761038A5084050969 @default.
• W4361761038 hasBestOaLocation W43617610381 @default.
• W4361761038 hasConcept C126322002 @default.
• W4361761038 hasConcept C134018914 @default.
• W4361761038 hasConcept C151730666 @default.
• W4361761038 hasConcept C2776919658 @default.
• W4361761038 hasConcept C2777180221 @default.
• W4361761038 hasConcept C2777391703 @default.
• W4361761038 hasConcept C2777451236 @default.
• W4361761038 hasConcept C2777910003 @default.
• W4361761038 hasConcept C2778081065 @default.
• W4361761038 hasConcept C2778163477 @default.
• W4361761038 hasConcept C2778670441 @default.
• W4361761038 hasConcept C2778913445 @default.
• W4361761038 hasConcept C2779306644 @default.
• W4361761038 hasConcept C2780323712 @default.
• W4361761038 hasConcept C2780762169 @default.
• W4361761038 hasConcept C2780988686 @default.
• W4361761038 hasConcept C555293320 @default.
• W4361761038 hasConcept C71924100 @default.
• W4361761038 hasConcept C86803240 @default.
• W4361761038 hasConcept C90924648 @default.
• W4361761038 hasConceptScore W4361761038C126322002 @default.
• W4361761038 hasConceptScore W4361761038C134018914 @default.
• W4361761038 hasConceptScore W4361761038C151730666 @default.
• W4361761038 hasConceptScore W4361761038C2776919658 @default.
• W4361761038 hasConceptScore W4361761038C2777180221 @default.
• W4361761038 hasConceptScore W4361761038C2777391703 @default.
• W4361761038 hasConceptScore W4361761038C2777451236 @default.
• W4361761038 hasConceptScore W4361761038C2777910003 @default.
• W4361761038 hasConceptScore W4361761038C2778081065 @default.
• W4361761038 hasConceptScore W4361761038C2778163477 @default.
• W4361761038 hasConceptScore W4361761038C2778670441 @default.
• W4361761038 hasConceptScore W4361761038C2778913445 @default.
• W4361761038 hasConceptScore W4361761038C2779306644 @default.
• W4361761038 hasConceptScore W4361761038C2780323712 @default.
• W4361761038 hasConceptScore W4361761038C2780762169 @default.
• W4361761038 hasConceptScore W4361761038C2780988686 @default.
• W4361761038 hasConceptScore W4361761038C555293320 @default.
• W4361761038 hasConceptScore W4361761038C71924100 @default.
• W4361761038 hasConceptScore W4361761038C86803240 @default.
• W4361761038 hasConceptScore W4361761038C90924648 @default.
• W4361761038 hasIssue "3" @default.
• W4361761038 hasLocation W43617610381 @default.
• W4361761038 hasLocation W43617610382 @default.

• next